A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Prelude Therapeutics
Prelude Therapeutics
Takeda
NuCana plc
Highlight Therapeutics
ADC Therapeutics S.A.
University of Florida
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
Incyte Corporation
M.D. Anderson Cancer Center
Western Regional Medical Center
Aduro Biotech, Inc.